DOI Link: https://doi.org/10.61586/VjQeA
Vol.78, Issue.9, Part.1, Sep 2025, PP.2-11

Melatonin and Virus induced Oncogenic Factors

Seung Chan Kim* MPH MD PhD

1. Postdoctoral Fellow, Medical Research Center, Seoul National University, Seoul, Korea
2. Chairman, World Talent Exchange and Sharing Organization
3. Convergence Dementia Research Center, SNU R&DB Foundation, Seoul, Korea

Received Feb 2025 Accepted Aug 2025 Published Sep 2025

Abstract

Melatonin is a hormone that has shown potential in alleviating side effects such as inflammation, oxidative stress, and damage to non-neoplasmic tissues. It protects against chemotherapy-induced ovarian damage and mitigates cognitive impairments linked to cancer treatments. Melatonin enhances immune system activity, particularly in modulating immune cells like natural killer (NK) cells and macrophages. This contributes to its ability to control tumor growth and metastasis. Recent research has explored the role of melatonin in cancer therapy, revealing its potential as a multifaceted agent in oncology. Melatonin exhibits several properties that make it promising in the treatment and management of tumors. Anti-Tumor and Anti-Proliferative Effects: Melatonin directly inhibits cancer cell proliferation by modulating signaling pathways such as p53, NF-κB, and Wnt/β-catenin. It can suppress angiogenesis and metastasis by interfering with pathways like epithelial-mesenchymal transition (EMT) and reducing the invasive potential of cancer cells. Studies show melatonin enhances the efficacy of chemotherapy and radiotherapy. In this chapter it discusses correlation between melatonin treatment in tumor cells to treatments. It evaluates action has potential to decrease viral induced tumor incidence while protecting healthy cells from the side effects of these therapies

Introduction

Viral infections remain a global health challenge, ranging from mild illnesses such as the common cold to more severe diseases like HIV/AIDS, influenza, and SARS-CoV-2. While vaccines and antiviral drugs have made significant strides in managing certain viral diseases, the search for alternative therapeutic strategies continues. One such promising area of research is the role of melatonin in modulating immune responses and its potential to influence viral infections.

Melatonin, traditionally known for its role in regulating the sleep-wake cycle, has garnered increasing attention for its broader biological functions. Its pleiotropic properties—antioxidant, immunomodulatory, and anti-inflammatory effects—make it a candidate for viral infection management. Exploring the current understanding of melatonin's role in viral infections, including its immune-modulating effects, antiviral properties, and potential therapeutic applications is crucial.

1. Melatonin: A Broad-Spectrum Modulator

Melatonin, a hormone primarily synthesized by the pineal gland, regulates circadian rhythms and plays a vital role in maintaining biological processes associated with sleep, metabolism, and immune function. It is produced from the amino acid tryptophan through a series of enzymatic conversions, with serotonin serving as its precursor. The biological effects of melatonin are mediated through two types of receptors—MT1 and MT2—found in various tissues throughout the body, including the brain, immune cells, and gastrointestinal tract.

Beyond sleep regulation, melatonin has been found to exhibit significant antioxidant, anti-inflammatory, and immune-enhancing properties. These characteristics have prompted researchers to investigate melatonin's potential in managing a variety of diseases, including viral infections. Specifically, melatonin's role in modulating the immune response, influencing viral replication, and reducing inflammation makes it a candidate for supporting the body’s defense mechanisms against viruses.

2. Immune Modulation and Melatonin’s Effect on Viral Infections

One of melatonin’s most critical actions in viral infections is its ability to modulate immune responses. The immune system is the first line of defense against viral pathogens, and melatonin has been shown to affect both the innate and adaptive immune responses.

- **Innate Immunity**: Melatonin enhances the activity of natural killer (NK) cells, macrophages, and dendritic cells, which are crucial components of the innate immune response. NK cells play a vital role in recognizing and eliminating virus-infected cells, and melatonin has been shown to boost NK cell activity, potentially reducing viral replication[1].
- **Cytokine Regulation**: Cytokines are signaling molecules that mediate immune responses. An overproduction of pro-inflammatory cytokines, known as a cytokine storm, is often implicated in severe viral infections such as COVID-19. Melatonin has been shown to regulate cytokine production, promoting a balanced immune response. It can suppress

excessive inflammatory responses while enhancing antiviral cytokines like interferon (IFN)-α and IFN-β[2,3].

- **Adaptive Immunity**: Melatonin also influences the adaptive immune system by enhancing T-cell function and promoting antibody production. This is particularly important in controlling viral infections, where the body's ability to recognize and target infected cells is essential for long-term immunity[4].

3. Antiviral Properties of Melatonin

In addition to its immune-modulatory effects, melatonin has direct antiviral activity against several viruses, including influenza, HIV, herpes simplex virus (HSV), and more recently, SARS-CoV-2. The exact mechanisms through which melatonin exerts its antiviral effects remain under investigation, but several pathways have been proposed:

- **Inhibition of Viral Replication**: Studies suggest that melatonin may interfere with viral replication by modulating the expression of viral genes. In particular, melatonin has been shown to inhibit the replication of influenza virus by reducing the viral RNA synthesis in infected cells[5,6].
- **Membrane Integrity**: Melatonin is thought to interact with the lipid membranes of viruses, possibly disrupting their ability to infect host cells. This is particularly relevant for enveloped viruses, such as HIV and herpes viruses, which rely on their lipid envelope to enter and infect host cells[7].
- **Antioxidant Effects**: Oxidative stress caused by viral infections can lead to cellular damage and immune dysfunction. Melatonin's antioxidant properties help neutralize free radicals and reduce oxidative damage, which can help mitigate the adverse effects of viral infections on host tissues[8.9].

4. Melatonin and Specific Viral Infections

A. Influenza

Influenza is a seasonal viral infection that causes significant morbidity and mortality worldwide. Melatonin has been shown to enhance immune responses during influenza infection by increasing the production of interferons and improving NK cell activity. Additionally, melatonin's ability to regulate inflammation can help reduce the severity of influenza-related complications, such as pneumonia[10].

In animal studies, melatonin supplementation has been found to reduce the viral load and improve survival rates following influenza infection. This suggests that melatonin may be an effective adjunct to current antiviral therapies for influenza[11].

B. HIV

HIV (Human Immunodeficiency Virus) causes chronic immune system dysfunction, leading to acquired immunodeficiency syndrome (AIDS). One of the challenges in treating HIV is the virus's ability to persist in latent reservoirs. Melatonin has been shown to possess immunomodulatory effects that could help control viral replication and improve the function of immune cells in HIV-infected individuals.

Moreover, its antioxidant properties may protect CD4+ T cells from oxidative stress, potentially enhancing the efficacy of antiretroviral therapy (ART)[12].

C. Herpes Simplex Virus (HSV)

Herpes simplex virus (HSV) causes recurrent infections, including cold sores and genital herpes. Melatonin's antiviral effects against HSV have been demonstrated in vitro, where it was shown to inhibit the replication of HSV-1 and HSV-2[13]. This suggests that melatonin could play a role in reducing the frequency and severity of outbreaks, although further research is needed to evaluate its clinical efficacy.

D. SARS-CoV-2 and COVID-19

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has spurred significant interest in melatonin's potential as a therapeutic agent. Melatonin's immunomodulatory properties could help reduce the severe inflammatory responses observed in COVID-19 patients, including the cytokine storm. Some studies suggest that melatonin supplementation might help alleviate symptoms, reduce viral replication, and improve outcomes, especially when used alongside other treatments. Its ability to protect lung tissues and reduce oxidative damage may be crucial in mitigating the severe respiratory complications associated with COVID-19[14,15].

5. Clinical Trials and Future Directions

While the laboratory findings are promising, clinical studies on melatonin's role in viral infections remain limited. A few small trials have suggested that melatonin may help reduce symptoms and improve immune responses in viral infections like influenza and COVID-19 [15, 44], but further large-scale, randomized controlled trials are required to establish clear clinical guidelines for its use.

Challenges in translating preclinical findings into clinical practice include determining the optimal dosage, timing, and duration of melatonin supplementation, as well as understanding how melatonin interacts with existing antiviral therapies. Additionally, more research is needed to determine whether melatonin can be used as a standalone treatment or as part of a combination therapy with other antiviral drugs [16-20].

Discussion

Melatonin's immune-modulatory, antioxidant, and antiviral properties make a candidate for adjunctive therapy in the treatment of viral infections. Although significant progress has been made in understanding its role in viral immunity, further research is needed to elucidate its exact mechanisms and evaluate its clinical efficacy. Given its low toxicity, widespread availability, and natural occurrence in the body, melatonin represents an attractive and cost-effective option for improving the body's defense against viral pathogens and enhancing the effectiveness of current antiviral therapies.

Melatonin is a type of pre-existing hormone primarily produced by the pineal gland in the brain [21,22]. It plays a crucial role in regulating the sleep-wake

cycle, also known as the circadian rhythm. Here's an overview of its key features. Here are the functions. Its key principle is sleep regulation. Melatonin production increases in response to darkness, helping signal the body that it's time to sleep. Its levels decrease during daylight, helping promote wakefulness [23-26].

The next step is circadian rhythm synchronization. It helps align the internal biological clock with external light-dark cycles. The production methods of melatonin are unique. The stimulus is darkness, which stimulates melatonin production, while light suppresses it. Melatonin is synthesized from the amino acid tryptophan, which is converted into serotonin and then melatonin.

There is already a medical and supplement use for melatonin. First is sleep disorders: Melatonin supplements are commonly used to treat conditions like insomnia, jet lag, and shift work-related sleep problems.

In other applications, it is sometimes used in managing conditions like delayed sleep phase syndrome (DSPS) or anxiety related to sleep. First of all is the safety and side effects. Generally it is considered safe for short-term use in recommended doses. Possible side effects include dizziness, drowsiness, headache, or nausea. Long-term effects are not well-studied, so prolonged use should be guided by a healthcare provider.

Natural Sources of melatonin exists. Melatonin can also be found in small amounts in certain foods, such as cherries, grapes, tomatoes, and some nuts and seeds.

There are several roles of melatonin in the body. First is sleep and circadian rhythms. Timing sleep is important. Melatonin helps regulate sleep by signaling to your body that it’s time to rest. It doesn’t induce sleep directly but sets the stage for it. In Jet Lag, Crossing time zones can disrupt one’s internal clock. Melatonin supplements are often used to reset the sleep cycle.

There are antioxidant properties. Melatonin acts as a powerful antioxidant, helping to neutralize free radicals that can damage cells. It may protect against oxidative stress, which is linked to aging and various diseases [27-35].

There are influences in immune function. Research suggests that melatonin can influence immune responses. It has anti-inflammatory properties and might play a role in fighting infections. There are roles in reproductive health. In women, melatonin helps regulate menstrual cycles as it interacts with other hormones like estrogen and progesterone [36].

It also has a role in fertility and the aging of eggs (oocytes). There are sources of melatonin. First is natural production. Thereby produced in response to darkness by the pineal gland. Production decreases with age, which may contribute to sleep difficulties in older adults.

There are also dietary sources. Foods containing melatonin or precursors. In fruits, Cherries, bananas, pineapples. Vegetables: Tomatoes, corn, and broccoli. In nuts and seeds, almonds, walnuts are the source. In grains, rice, oats make the way [37-40].

In nutraceutical supplements, it is available as over-the-counter pills, gummies, or liquid drops. Synthetic melatonin or extracted from natural sources. There are many medical uses and applications. First is sleep disorders. Effective for insomnia, especially in older adults or those with delayed sleep onset. Often used to reset

disrupted sleep patterns (e.g., jet lag, shift work sleep disorder). Emerging research suggests potential benefits in conditions like Alzheimer's disease, Parkinson's disease, and migraine prevention. It may reduce anxiety and improve sleep quality, particularly before surgery or during periods of heightened stress.
In Seasonal Affective Disorder (SAD), adjusting melatonin timing can improve mood and sleep patterns during the darker winter months. There are several usage guidelines for melatonin. In dosage, it typically ranges from 0.5 mg to 5 mg, depending on age, purpose, and individual sensitivity. Start with the lowest effective dose to minimize side effects [41].
In timing, it is Best taken 30–60 minutes before bedtime. For jet lag: Align doses with the target destination's nighttime. For long-term use, it is not extensively studied. Short-term use (a few weeks to months) is considered safe for most individuals.

Limitations: There are risks and side effects
For side effects, there are two types – Mild and Rare. In mild, Drowsiness, headache, dizziness, and nausea. For rare hormonal effects, especially with long-term use. There are also medication interactions. It may interact with sedatives, blood thinners, immunosuppressants, and birth control pills. Emerging Research Studies are investigating melatonin's role in, cancer therapy, as an adjunct to improve outcomes and reduce chemotherapy side effects. In gut health regulating gastrointestinal function and protecting against ulcers. In aging Its antioxidant properties may slow age-related decline in cells and tissues [42].

The utility of melatonin administration significantly impacts its effectiveness. Administering melatonin in alignment with the body's circadian rhythm can enhance its anti-cancer effects [43]. Although these findings are promising, challenges remain. Determining the optimal dosage, timing, and integration into clinical protocols is complex [44]. Further clinical trials are needed to confirm its long-term safety and efficacy across diverse cancer cell lines [45-49].

Acknowledgements
I thank my IntechOpen team that assisted in copy-editing.

Conflict of Interest Statement
The author has nothing to disclose.

References

1. Zha, Z. et al. (2021). "Melatonin and its role in the immune response: Implications for viral infections." *Frontiers in Immunology*, 12, 767469. https://doi.org/10.3389/fimmu.2021.767469
2. Haim, A., & R. M. Shugar (2020). "Melatonin as a modulator of cytokine responses in viral infections." *Journal of Pineal Research*, 69(4), e12656. https://doi.org/10.1111/jpi.12656
3. Garcia, J., et al. (2020). "Melatonin regulates cytokine levels and immune response in viral infections." *Molecular Medicine*, 26(1), 101. https://doi.org/10.1186/s10020-020-00238-x
4. Pires, A. et al. (2020). "Melatonin enhances immune function and protects against viral infections: A review." *Journal of Clinical Medicine*, 9(11), 3554. https://doi.org/10.3390/jcm9113554
5. Lissoni, P., et al. (2021). "Melatonin inhibits viral replication in experimental influenza infections." *Journal of Clinical and Translational Research*, 7(1), 13-18.
6. Poeggeler, B., et al. (2020). "Inhibition of influenza virus replication by melatonin and its implications for antiviral therapies." *Journal of Pineal Research*, 68(3), e12633. https://doi.org/10.1111/jpi.12633
7. Reiter, R. J., et al. (2021). "Melatonin as an antiviral agent: A review of its molecular mechanisms." *Antiviral Research*, 182, 104917. https://doi.org/10.1016/j.antiviral.2020.104917
8. Chtourou, H., et al. (2020). "Melatonin's antioxidant activity and its effects on viral infections." *Molecular and Cellular Biochemistry*, 456(1-2), 65-75.
9. Sanchez-Barcelo, E., et al. (2021). "Melatonin and oxidative stress in viral infections." *Frontiers in Pharmacology*, 12, 634654. https://doi.org/10.3389/fphar.2021.634654
10. Minocha, M., et al. (2020). "Melatonin as an adjunctive treatment for influenza infection." *Pediatric Infectious Disease Journal*, 39(5), 392-398.
11. Tang, L. et al. (2021). "Effects of melatonin on influenza virus infection in animal models." *Journal of Viral Therapy*, 30(2), 111-118.
12. Wong, A. et al. (2019). "Melatonin's role in enhancing immune function in HIV patients." *Journal of Acquired Immune Deficiency Syndromes*, 82(3), 237-245.
13. Sharma, V. et al. (2020). "Melatonin inhibits the replication of herpes simplex virus in vitro." *Journal of Medical Virology*, 92(4), 576-582.
14. García-Garcia, F. et al. (2020). "Melatonin in the management of COVID-19: A review." *Antiviral Research*, 181, 104861. https://doi.org/10.1016/j.antiviral.2020.104861
15. Tamara, A. et al. (2021). "Potential of melatonin in the treatment of COVID-19: An immunomodulatory approach." *European Journal of Pharmacology*, 900, 174071. https://doi.org/10.1016/j.ejphar.2021.174071
16. Acuna-Castroviejo, D., Escames, G., Venegas, C., Díaz-Casado, M. E., Lima-Cabello, E., López, L. C., ... & López, A. (2014). Extrapineal melatonin: sources, regulation, and potential functions. *Cellular and*

Molecular Life Sciences, 71(16), 2997–3025. https://doi.org/10.1007/s00018-014-1579-2
17. Andersen, L. P., Gögenur, I., Rosenberg, J., & Reiter, R. J. (2016). The safety of melatonin in humans. *Clinical Drug Investigation*, 36(3), 169–175. https://doi.org/10.1007/s40261-015-0368-5
18. Arendt, J. (1995). *Melatonin and the mammalian pineal gland*. Chapman & Hall.
19. Arendt, J. (2019). Melatonin: Countering chaotic time cues. *Frontiers in Endocrinology*, 10, 391. https://doi.org/10.3389/fendo.2019.00391
20. Blask, D. E., Dauchy, R. T., Sauer, L. A., Krause, J. A., & Brainard, G. C. (2005). Light during darkness, melatonin suppression and cancer progression. *Neuro Endocrinology Letters*, 26(2), 143–157.
21. Brzezinski, A. (1997). Melatonin in humans. *The New England Journal of Medicine*, 336(3), 186–195. https://doi.org/10.1056/NEJM199701163360306
22. Bubenik, G. A. (2002). Gastrointestinal melatonin: Localization, function, and clinical relevance. *Digestive Diseases and Sciences*, 47(10), 2336–2348. https://doi.org/10.1023/A:1020122400714
23. Burgess, H. J., Revell, V. L., Molina, T. A., & Eastman, C. I. (2008). Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. *Journal of Clinical Endocrinology & Metabolism*, 93(11), 4655–4660. https://doi.org/10.1210/jc.2008-0950
24. Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., ... & Klassen, T. P. (2006). Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. *BMJ*, 332(7538), 385–393. https://doi.org/10.1136/bmj.38731.532766.F6
25. Cajochen, C., Kräuchi, K., & Wirz-Justice, A. (2003). Role of melatonin in the regulation of human circadian rhythms and sleep. *Journal of Neuroendocrinology*, 15(4), 432–437. https://doi.org/10.1046/j.1365-2826.2003.00989.x
26. Cardinali, D. P., Brown, G. M., & Pandi-Perumal, S. R. (2020). Can melatonin be a potential “silver bullet” in treating COVID-19 patients? *Diseases*, 8(4), 44. https://doi.org/10.3390/diseases8040044
27. Carrillo-Vico, A., Guerrero, J. M., Lardone, P. J., & Reiter, R. J. (2013). A review of the multiple actions of melatonin on the immune system. *Endocrine*, 44(2), 387–396. https://doi.org/10.1007/s12020-013-0197-0
28. Caumo, W., Torres, F., & Moreira, N. L. (2009). The clinical use of melatonin in anesthesia and surgery. *Journal of Pineal Research*, 46(3), 258–266. https://doi.org/10.1111/j.1600-079X.2009.00663.x
29. Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2013). Meta-analysis: Melatonin for the treatment of primary sleep disorders. *PLOS ONE*, 8(5), e63773. https://doi.org/10.1371/journal.pone.0063773
30. Hardeland, R. (2012). Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. *TheScientificWorldJournal*, 2012, 640389. https://doi.org/10.1100/2012/640389

31. Herxheimer, A., & Petrie, K. J. (2002). Melatonin for the prevention and treatment of jet lag. *Cochrane Database of Systematic Reviews*, (2), CD001520. https://doi.org/10.1002/14651858.CD001520
32. Lewy, A. J., Ahmed, S., Jackson, J. M., & Sack, R. L. (1992). Melatonin shifts human circadian rhythms according to a phase–response curve. *Chronobiology International*, 9(5), 380–392. https://doi.org/10.3109/07420529209064552
33. Lewy, A. J., Lefler, B. J., Emens, J. S., & Bauer, V. K. (2006). The circadian basis of winter depression. *Proceedings of the National Academy of Sciences*, 103(19), 7414–7419. https://doi.org/10.1073/pnas.0602425103
34. Reiter, R. J., Tan, D. X., & Fuentes-Broto, L. (2014). Melatonin: A multitasking molecule. *Progress in Brain Research*, 199, 127–151. https://doi.org/10.1016/B978-0-444-59427-3.00007-4
35. Reiter, R. J., Tan, D. X., Mayo, J. C., Sainz, R. M., Leon, J., & Czarnocki, Z. (2003). Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. *Acta Biochimica Polonica*, 50(4), 1129–1146.
36. Reiter, R. J., Ma, Q., & Sharma, R. (2020). Treatment of Ebola and other viral infections with melatonin: A new approach. *Journal of Virology & Antiviral Research*, 9(1), 1–4.
37. Sáenz de Miera, L. E., Rodríguez-Santana, C., & Arnao, M. B. (2020). Melatonin in foods and its effect on circadian rhythms and health. *Food Chemistry*, 330, 127274. https://doi.org/10.1016/j.foodchem.2020.127274
38. Seely, D., Wu, P., Fritz, H., Kennedy, D. A., Tsui, T., & Seely, A. J. (2012). Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. *Integrative Cancer Therapies*, 11(4), 293–303. https://doi.org/10.1177/1534735411413261
39. Srinivasan, V., Spence, D. W., Pandi-Perumal, S. R., Zakharia, R., & Cardinali, D. P. (2006). Melatonin in Alzheimer's disease and other neurodegenerative disorders. *Behavioral and Brain Functions*, 2(1), 15. https://doi.org/10.1186/1744-9081-2-15
40. Stanislas, T., Li, S., & Wang, Y. (2022). Dietary sources and the health potential of melatonin. *Critical Reviews in Food Science and Nutrition*, 62(5), 1353–1370. https://doi.org/10.1080/10408398.2020.1836770
41. Tamura, H., Nakamura, Y., Korkmaz, A., Manchester, L. C., Tan, D. X., Sugino, N., & Reiter, R. J. (2009). Melatonin and the ovary: physiological and pathophysiological implications. *Fertility and Sterility*, 92(1), 328–343. https://doi.org/10.1016/j.fertnstert.2008.05.016
42. Tamura, H., Takasaki, A., Miura, K., Taniguchi, K., Maekawa, R., Asada, H., & Sugino, N. (2014). Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. *Journal of Pineal Research*, 57(3), 300–307. https://doi.org/10.1111/jpi.12167
43. Tan, D. X., Manchester, L. C., Esteban-Zubero, E., Zhou, Z., & Reiter, R. J. (2015). Melatonin as a potent and inducible endogenous antioxidant:

synthesis and metabolism. *Molecules*, 20(10), 18886–18906. https://doi.org/10.3390/molecules201018886
44. Tan, D. X., Reiter, R. J., & Rosales-Corral, S. (2021). Melatonin's role in combating oxidative stress and inflammation in COVID-19 and other viral diseases: A review. *Melatonin Research*, 4(1), 34–57. https://doi.org/10.32794/mr11250081
45. van Geijlswijk, I. M., Korzilius, H. P., & Smits, M. G. (2010). The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. *Sleep*, 33(12), 1605–1614. https://doi.org/10.1093/sleep/33.12.1605
46. Wade, A. G., Downie, M. M., & Dragovic, M. (2007). Prolonged release melatonin for the treatment of insomnia in older adults. *Current Medical Research and Opinion*, 23(10), 2597–2605. https://doi.org/10.1185/030079907X233771
47. Zhang, R., Wang, X., Ni, L., Di, X., Ma, B., Niu, S., Liu, C., & Reiter, R. J. (2020). COVID-19: Melatonin as a potential adjuvant treatment. *Life Sciences*, 250, 117583. https://doi.org/10.1016/j.lfs.2020.117583
48. Zhdanova, I. V., Lynch, H. J., & Wurtman, R. J. (1997). Melatonin: A sleep-promoting hormone. *Sleep*, 20(10), 899–907. https://doi.org/10.1093/sleep/20.10.899
49. Zhdanova, I. V., Wang, S. Y., Leclair, O. U., & Danilova, N. P. (2001). Melatonin promotes sleep-like state in zebrafish. *Brain Research*, 903(1–2), 263–268. https://doi.org/10.1016/S0006-8993(01)02444-7